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ABSTRACT 
Increasing trend of antibiotic resistance and expression of Extended Spectrum Beta Lactamases (ESBLs) are se-
rious threats for public health as they render the treatment ineffective. Present study was designed to elucidate 
the antibiotic-susceptibility patterns of ESBL and non-ESBL producing E. coli and K. pneumoniae causing uri-
nary tract infections so that the ineffective antibiotics could be removed from the line of treatment. The bacterial 
isolates obtained from the urine of patients visiting a tertiary health care facility were cultured for strain identifi-
cation using API20E. Antimicrobial susceptibility and ESBL detection were done by Kirby-bauer diffusion 
technique. Almost 53.4 % isolates of E. coli and 24.5 % isolates of K. pneumoniae were found to be ESBL pro-
ducers. The ESBL producing bacteria were found to be more resistant towards various antibiotics. The most ef-
fective drugs against E. coli ESBL isolates were imipenem (99.54 %), ampicillin-sulbactam (97.48 %), piperacil-
lin-tazobactam (96.86 %), fosfomycin (94.51 %), amikacin (92.26 %) and nitrofurantoin (90.68 %). The most ef-
fective drugs against K. pneumoniae ESBL isolates were imipenem (97.62 %), piperacillin-tazobactam 
(95.35 %), ampicillin-sulbactam (90.48 %) and amikacin (88.37 %). The antibiotics having the highest re-
sistance, particularly by the ESBL producers were amoxicillin clavulanic acid, sulphamethoxalzole/ trime-
thoprim, cefuroxime, cefpirome, ceftriaxone and ciprofloxacin. Most of the isolates showed multi drug resistance 
(MDR). High frequency of ESBL producing E. coli and K. pneumoniae were observed as compared to previous 
data. Penicillins, cephalosporins and some representatives of fluoroquinolones were least effective against the 
common UTIs and are recommended to be removed from the line of treatment. 
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INTRODUCTION 
Microbes causing urinary tract infections 
(UTIs) affect all age and gender groups 
unanimously. Clinical manifestations of 
UTIs vary greatly leading to severe morbidi-
ty and even mortality. Uropathogenic organ-
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isms are mostly human intestinal commen-
sals. These organisms show virulent behav-
ior upon transmission to clinically significant 
biological sites (Boye and Hansen, 2003; 
Jonas et al., 2004). Escherichia coli, a 
facultative anaerobe and gram negative 
bacillus, has been reported as the most 
prevalent microbe followed by Klebsiella 
pneumoniae and other pathogens like 
Staphylococcus, Proteus, Pseudomonas, 
Enterococcus, and Enterobacter (Farrel et 
al., 2003; Mirsoleymani et al., 2014). In the 
past few years, an increasing trend in the 
antibiotic resitance imparted by E. coli and 
K. pneumoniae isolates has been observed. 
This worrisome shift in resistance is posing a 
greater therapeutic challenge (Sharma et al., 
2007) as the treatment of UTIs is often im-
paired due to the resistance of leading patho-
gens to commonly used antimicrobial agents 
(Chakupurakal et al., 2010; Souli et al., 
2010). One of the resistance mechanisms 
developed by E. coli and K. pneumoniae is 
the phenotypic expression of plasmid 
mediated genes encoding Extended 
Spectrum Beta Lactamases (ESBL). Most of 
the beta lactam antibiotics used in the 
treatment of clinical bacteriuria are rendered 
non-susceptible by these enzymes. The 
prevalence of ESBL producing strains is 
found to be higher than other resistant 
phenotypes proving them as threat for 
clinical management (Hyle et al., 2005). The 
malpractices leading to resistant attributes of 
microorganisms include substandard antibi-
otic quality, unhygienic environment respon-
sible for transmission of resistant strains, in-
adequate surveillance and antibiotic admin-
istration by health professionals and misuse 
by patients (Okeke et al., 2005). Treatment 
options have become limited due to the dras-
tic increase in resistance against various 
classes of antibiotics including fluoroquino-
lones and all cephalosporin generations. This 
phenomenon can augment the severity of 
even a simple UTI (Shariff et al., 2013). The 
antibiotic susceptibility of pathogens show 
high inter regional variation and is linked to 
the clinical practices of physicians and 
medication practices of patients along with 
evolutionary resistance which make certain 
pathogens more resistant over time. This 
study was undertaken to determine the 
antibiotic susceptibility patterns of ESBL 
and non-ESBL producing E. coli and K. 
pneumoniae in a tertiary care facility in 
Islamabad, Pakistan. 
 
METHODOLOGY 
The samples were collected at Depart-
ment of Microbiology, Pakistan Institute of 
Medical Sciences, Islamabad, Pakistan, from 
patients visiting the hospital with clinical 
symptoms of urinary tract infection. The 
study was ethically approved from the 
Institutional Review Board of Quaid-i-Azam 
University, Islamabad, Pakistan. Informed 
consent was obtained from the patients 
before including them in the study. The 
patients were guided to pass the midstream 
urine sample by un-touched, sterile 
technique in a wide-mouth screw capped 
sterile container. A total of 6254 urine 
samples were collected from males and 
females belonging to all age groups. 
For the screening of bacterial infection, 
the urine samples were cultured on blood 
agar and MacConkey agar plates and the co-
lony morphology was studied after 24 hours 
incubation at 37 °C. Colonies from agar plate 
isolates were smeared on glass slides and 
stained with Gram’s stain using Preston’s 
and Morrells modification (Cheesbrough, 
2006) to examine for Gram’s reaction, 
colour, size, shape and distribution of the mi-
crorganisms. The strains were further tested 
for ESBL phenotye using disc diffusion 
method by applying panel of beta lactam 
drugs (cefuroxime, ceftriaxone, cefpirome 
and imipenem) followed by strain identi-
fication by Analytical Profile Index (API 20 
E). Susceptibility of the isolates was 
determined against a panel of antibiotic discs 
including augmentin, cefuroxime, ceftriax-
one, cefpirome, norfloxacin, ciprofloxacin, 
amikacin, gentamicin, sulfamethoxalzole-
trimethoprim, nitrofurantoin, fosfomycin, 
imipenem, ampicillin-sulbactam, piperacil-
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lin-tazobactam. CLSI guidelines were used 
for susceptibility markers of each of the an-
tibiotics applied to declare the antibiotic as 
resistant or sensitive. 
Two-sided Student's t-tests were used to 
detect statistically significant differences be-
tween study groups, using StatSoft's Statisti-
ca software. Fischer Exact test was applied 
on non-parametric dichotomous variables. P 
values below 0.05 were considered statisti-
cally significant, and P values below 0.001 
were considered highly significant. 
 
RESULTS 
ESBL production among urinary tract 
pathogens  
A total of 6254 urine samples were 
collected from patients attending the 
healthcare facility and were processed for 
microbial screening. 1362 (21.8 %) samples 
were positive for bacterial infections while 
the remaining 4892 were negative and thus 
not processed further. Out of 1362, 1039 
(76.3 %) samples showed Escherichia coli 
infection, 163 (12.0 %) cases were of 
Klebsiella pneumoniae, while the remaining 
cases corresponded to Pseudomonas spp., 
Proteus spp., Enterobacter spp., Acinetobac-
ter spp., Enterococcus spp., Staphylococcus 
spp. and Streptococcus spp. (Table 1). 
Among 1039 E. coli isolates, ESBL 
producing isolates were 484 (46.6 %) while 
the negative isolates for ESBL production 
were 555 (53.4 %). ESBL producing K. 
pneumoniae isolates were 40/163 (24.5 %) 
while the K. pneumoniae isolates negative 
for ESBL production were 123/163 (75.4 %). 
 
Higher UTI prevalence in female 
population 
Among the patients suffering from infection 
by non-ESBL E. coli isolates, 104/555 
(18.7 %) were males and 451/555 (81.3 %) 
were females (Figure 1A). Among the ESBL 
producing isolates of E. coli, 100/484 
(20.7 %) were infecting males while 384/484 
(79.3 %) were infecting females. Regarding 
K. pneumoniae, 32/123 (26 %) patients 
affected by non-ESBL K. pneumoniae were 
males while 91/123 (74 %) were females. 
ESBL producing K. pneumoniae affected 
11/40 (27.5 %) males and 29/40 (72.5 %) 
females. Overall, 247/1202 (20.5 %) patients 
having UTI were males while the proportion 
of females was significatly higher i.e. 
955/1202 (79.5 %).  
 
Age distribution of patients suffering from 
urinary tract infections 
Patients suffering from urinary tract 
infections due to bacterial pathogens 
belonged to all age groups. Most of the 
patients (251/1202; 20.9 %) reporting UTIs 
were between 51-60 years of age. 14.6 % 
patients were 71-80 years old, 13.7 % 
patients were 61-70 years old and 12.9 % 
patients were 21-30 years of age. It is 
notable that prevalence of UTIs was also 
quite high in children aged 01-10 years as 
10.4 % patients belonged to this age group. 
The details are given in Figure 1B.  
 
Antibiotic susceptibility testing of 
Escherichia coli isolates  
The ESBL producing bacteria were 
found to be more resistant towards various 
antibiotics as compared to non-ESBL 
pathogens (Figures 2A and 2B; Table 2). The 
most effective drugs found in susceptibility 
 
 
Table 1: Prevalence of ESBL and non-ESBL 
producing E. coli and K. pneumoniae among uri-
nary isolates 
Samples Number
Total samples evaluated 6254 
 Positive for bacterial infection 1362 
 Negative for bacterial infection 4892 
Escherichia coli 1039 
 ESBL producing E. coli 484 
 Non-ESBL E. coli 555 
Klebsiella pneumoniae 163 
 ESBL producing  
K. pneumoniae 40 
 Non-ESBL K. pneumoniae 123 
ESBL, extended spectrum beta lactamase 
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. 
Figure 1:  
A) Gender dis-
tribution of ESBL 
and non-ESBL 
producing E. coli 
and K. pneu-
moniae isolates 
causing urinary 
tract infections. 
B) Prevalence of 
urinary tract in-
fections among 
various age 
groups.  
*p < 0.05; **p < 0.001;  
ESBL, extended spectrum 
beta lactamase 
Figure 2: 
A) Antibiotic suscep-
tibility patterns of 
ESBL and non-ESBL 
producing E. coli iso-
lates against routine-
ly used antibiotics. 
B) Antibiotic suscep-
tibility patterns of 
ESBL and non-ESBL 
producing K. pneu-
moniae isolates 
against routinely 
used antibiotics.  
*p < 0.05; **p < 0.001; 
ESBL, extended spectrum 
beta lactamase; AMC, 
Amoxicillin-clavulanic ac-
id; CXM, Cefuroxime; 
CRO, Ceftriaxone; CPO, 
Cefpirome; NOR, Norflox-
acin; CIP, Ciprofloxacin; 
AK, Amikacin; CN, Gen-
tamicin; SXT, Sulpha-
methoxalzole/Trimetho-
prim; F, Nitrofurantoin; 
FOS, Fosfomycin; IPM, 
Imipenem; SCF, Ampicil-
lin-sulbactum; TZP, Pipe-
racillin-tazobactum 
EXCLI Journal 2015;14:916-925 – ISSN 1611-2156 
Received: February 24, 2015, accepted: June 17, 2015, published: August 04, 2015 
 
 
920 
 
 
Table 2: Susceptibility of ESBL and non-ESBL producing E. coli and K. pneumoniae to routinely used antibiotics 
Infectious  
Agent AMC SXT CXM CPO CRO CIP F CN NOR FOS AK SCF TZP IPM 
E. coli  
(non-ESBL) 69.02
a 39.13 77.98 80.77 81.67 54.68 91.37 77.67 54.11 95.57 96.7 97.93 97.51 99.06 
E. coli  
(ESBL) 2.08 12.58 0 1.71 1.05 12.61 90.68 55.41 12.55 94.51 92.26 97.48 96.86 99.54 
P < 0.001b p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p > 0.05 p < 0.001 p < 0.001 p > 0.05 p < 0.05 p > 0.05 p > 0.05 p > 0.05 
K. pneumoniae  
(non-ESBL) 26.05 40.52 60.42 65.38 71.19 58.47 51.85 79.81 76.03 85.29 90.48 92.45 97.84 99.53 
K. pneumoniae  
(ESBL) 2.27 2.27 2.44 4.44 4.76 25 52.5 55.81 75 76.92 88.37 90.48 95.35 97.62 
p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001 p > 0.05 p < 0.001 p > 0.05 p < 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 
 
apercentage of samples showing susceptibility to various antibiotics; bp < 0.001 – highly significant; p < 0.05 – significant; p > 0.05 – non-significant; AMC, Amoxicillin-clavulanic acid; CXM, Cefurox-
ime; CRO, Ceftriaxone; CPO, Cefpirome; NOR, Norfloxacin; CIP, Ciprofloxacin; AK, Amikacin; CN, Gentamicin; SXT, Sulphamethoxalzole/Trimethoprim; F, Nitrofurantoin; FOS, Fosfomycin; IPM, 
Imipenem; SCF, Ampicillin-sulbactum; TZP, Piperacillin-tazobactum 
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testing against E. coli ESBL isolates were 
imipenem (99.54 %), ampicillin-sulbactam 
(97.48 %), piperacillin-tazobactam (96.86 %), 
fosfomycin (94.51 %), amikacin (92.26 %) 
and nitrofurantoin (90.68 %). The non-ESBL 
producing isolates were also most suscept-
ible to the same antibiotics (Table 2). Signi-
ficant difference in susceptibility between 
ESBL and non-ESBL isolates was found in 
case of amoxycillin clavulanic acid, 
sulphamethoxalzole/trimethoprim, cefurox-
ime, cefpirome, ceftriaxone, ciprofloxacin 
and norfloxacin. The ESBL isolates of E. 
coli were extremely resistant to these set of 
antibiotics but on the contrary, non-ESBL 
isolates showed considerable sensitivity to 
them. The details are given in Figure 2A and 
Table 2.  
 
Antibiotic susceptibility testing of Klebsiella 
pneumoniae isolates  
The most effective drugs found in 
susceptibility testing against K. pneumoniae 
ESBL isolates were imipenem (97.62 %), 
piperacillin-tazobactam (95.35 %), ampicil-
lin-sulbactam (90.48 %) and amikacin 
(88.37 %). The non-ESBL producing isolates 
were also most susceptible to the same 
antibiotics (Figure 2B, Table 2). Significant 
difference in susceptibility between ESBL 
and non-ESBL isolates was found in case of 
beta lactam drugs amoxycillin clavulanic 
acid, sulphamethoxalzole/trimethoprim, ce-
furoxime, cefpirome, ceftriaxone and ciprof-
loxacin. The ESBL isolates of K. pneumo-
niae were highly resistant to these set of anti-
biotics; however, non-ESBL isolates showed 
relatively higher sensitivity to them. The de-
tails are given in Figure 2B and Table 2. 
 
DISCUSSION 
The most common type of urinary tract 
infection is the infection of bladder also 
known as cystitis. The major cause of cystitis 
is E. coli which is a type of bacteria 
commonly found in the gastrointestinal tract. 
It was observed that the prevalence of UTIs 
was considerably high in females as 
compared to males. One potential reason for 
cystitis is cross infection through sexual 
intercourse but women are generally more 
prone to UTIs because of their anatomy as 
distance from the urethra to the anus is short 
and so is the distance from the urethral 
opening to the bladder. All the age groups 
were affected by bacterial pathogens but 
majority of the population belonged to 50-60 
years of age. Young children were also 
affected by ESBL producing E. coli and K. 
pneumoniae. Presence of such resistant 
strains in children is alarming and is 
potentially linked with the prevalence of 
such strains in the surrounding people and 
environment (Fan et al., 2014).  
Antibiotic resistance is an important 
public heath concern around the globe. Beta 
lactam antibiotics are the most widely used 
antibiotics and contain a beta-lactam ring in 
their molecular structure and usually work 
by inhibiting bacterial cell wall biosynthesis. 
Often, bacterial pathogens develop resistance 
to beta-lactam antibiotics through the 
production of a beta-lactamase enzyme that 
attacks the beta-lactam ring and renders the 
beta-lactam antibiotics ineffective. Accord-
ing to the present findings, the drugs 
effective against ESBL producing isolates 
were essentially effective against the non-
ESBL producers as well. However, various 
drugs effective against non-ESBL producers 
did not work against ESBL-producing 
pathogens pointing towards the resistance 
posed by ESBL production.  
The current study reports the overall 
prevalence of ESBL producing E. coli to be 
46.6 % and K. pneumoniae to be 24.5 %. 
The ESBL production values are very high 
and in line with studies being done in Iran 
(67 %), Latin America (44.9 %), Bangladesh 
(43 %), India (42 %), United Arab Emirates 
(41 %), Kuwait (31.7 %), Greece (27.4 %), 
Bahrain (22.6 %) and Portugal (15.5 %). 
However, in some studies the prevalence of 
ESBL producing pathogens was as low as 
6.3 % (Saudi Arabia), 2.6 % (Germany) and 
2 % (Netherlands) (Winokur et al., 2001; 
Bouchillon et al., 2004; Rahman et al., 2004; 
Al-Zarouni et al., 2008; Mehrgan and Rah-
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bar, 2008; Mokaddas et al., 2008; Taneja et 
al., 2008; Bindayna et al., 2009). The 
comparatively low rates of ESBLs reflect 
appropriate use of antibiotics and effective 
implementation of infection control meas-
ures to control the spread of these strains. 
Carbapenems work by the inhibition of 
cell wall synthesis and are highly resistant to 
the beta-lactamase enzyme. The representa-
tive of this class, Imipenem was the most ef-
fective antibiotic against non-ESBL as well 
as ESBL-producing E. coli and K. pneu-
moniae according to the present findings. 
This is in line with the previous reports from 
India and Pakistan (Babypadmini and Appa-
laraju, 2004; Akram et al., 2007; Ullah et al., 
2009). Next in line for the effective man-
agement of UTIs were the penicillins given 
in combination with additional cell wall in-
hibitors e.g. Ampicillin-sulbactam and Pipe-
racillin-tozobactum. These combinations are 
more effective as both cohorts attack bacteri-
al cell wall; one by interfering with synthesis 
and other by enhancing degradation and thus 
rendering bacteria ineffective. These were 
again very potent against non-ESBL as well 
as ESBL-producing E. coli and K. pneu-
moniae. Piperacillin-tozobactum combina-
tion remains at the top (Sabir et al., 2014) 
while selecting drug of choice and in order to 
keep it on the long favorable track, this drug 
must be carefully advised and administered. 
Ampicillin-sulbactam; however, has shown 
better results as compared to a study in On-
tario, Canada where its effectiveness was on-
ly 81 % (Zhanel et al., 2000). This may be 
attributed to lesser use of this antibiotic in 
this part of the world. It is important to men-
tion that beta-lactam penicillins like ampicil-
lin, piperacillin, amoxicillin etc. have beta-
lactam ring and the ESBL-producers easily 
overcome their effect so they must be given 
in combination to guarantee their effect. 
Among amino glycosides, Amikacin has 
shown a good activity against clinically im-
portant gram negative bacilli as also reported 
in earlier studies (Winokur et al., 2001). The 
susceptibility of ESBL-producing E. coli 
against Amikacin was better than ESBL-
producing K. pneumoniae. Amikacin gener-
ally works through inhibition of bacterial 
protein synthesis by binding to 30s ribosome 
leading to misreading of mRNA. Based on 
the present findings, amikacin is a likely al-
ternative for empirical therapy when other 
agents cannot be used, but there are no clini-
cal data published on mono-therapy with this 
agent that would confidently support this ar-
gument. 
Based on ESBL production, contrary to 
Klebsiella pneumoniae, Escherichia coli iso-
lates were highly susceptible to fosfomycin 
which is similar to the findings of Falagas et 
al. (2010) suggesting that the E. coli have not 
yet developed any defense mechanism 
against this drug and it could be used as em-
pirical choice of treatment. However, it was 
not much effective against K. pneumoniae 
isolates as the resistance reached up to 24 %.  
Nitrofurantoin is a member of Nitrofu-
rans group of antibiotics and renders its bac-
tericidal activity through the damage of bac-
terial DNA. This antibiotic was effective 
against ESBL and non-ESBL producing E. 
coli but quite ineffective against ESBL and 
non-ESBL-producing K. pneumoniae iso-
lates suggesting their selection only for the 
former cases. The sensitivity reported by 
some previous studies was as high as 99.5 % 
but this value has now dropped to 90.7 % but 
still this drug could be used as first line 
choice to treat urinary tract infections caused 
by Escherichia coli (Zhanel et al., 2000). 
The Cephalosporins are beta-lactam anti-
biotics that disrupt the synthesis of the pepti-
doglycan layer of bacterial cell walls and 
thus compromise their structural integrity. 
However, the ESBL-producing E.coli and K. 
pneumoniae isolates showed up to 95 % re-
sistance to the cephalosporin representatives 
used in this study like cefuroxime, ceftriax-
one and cefpirome. All these members have 
shown much reduced susceptibility as com-
pared to previous studies which may be at-
tributed to the development of the potent re-
sistance mechanism involving the production 
of beta-lactamase enzyme (Shah et al., 
2002).  
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Amoxicillin–clavulanic acid was found 
to be least potent against the ESBL-produ-
cing E. coli and K. pneumoniae. Amoxicillin 
is a beta-lactam antibiotic so because of the 
emergence of ESBL production phenome-
non, it is given along with clavulanic acid 
which is a beta-lactamase inhibitor. Howev-
er, despite giving in combination with clavu-
lanic acid, such low efficacy points to some 
additional resistance mechanism unidentified 
so far. Some previous studies also showed 
compromised efficiency of augmentin but 
more than 95 % resistance suggests complete 
elimination of this drug from clinical prac-
tice (Rodríguez-Baño et al., 2004). 
Sulfamethoxalzole/Trimethoprim is a 
bactericidal which hinders the folic acid syn-
thesis in the bacterial cell and thus attacks 
the metabolism. This combination was again 
least potent against ESBL as well as non-
ESBL producing E. coli and K. pneumoniae. 
Some previous studies also showed similar 
findings and suggested to stop practicing the 
use of this antibiotic (Ullah et al., 2009). Ex-
tensive use of this antibiotic may have led to 
this level of resistance. By now, this drug 
cannot be suggested as an empirical therapy 
to treat UTIs in Pakistan. 
Among the non β-lactams, gentamicin 
showed higher affectivity against the bacteri-
al isolates as compared to Israel, India and 
some other regions of Pakistan (Tankhiwale 
et al., 2004; Colodner et al., 2007; Ullah et 
al., 2009). On the contrary, norfloxacin and 
ciprofloxacin, which are 2nd generation fluo-
roquinolones and work as DNA synthesis in-
hibitors, showed reduced effectiveness than 
reported by earlier studies which may be at-
tributed to increased resistance with time due 
to misuse of antibiotics and thus supports the 
hypothesis of this study (Shah et al., 2002).  
To summarize, this study shows that 
larger number of E. coli recovered from UTI 
in this region produce ESBLs. Thus, they are 
resistant to penicillins and cephalosporins, 
which are important drugs in the treatment of 
UTIs. Such isolates are also resistant to fluo-
roquinolones, aminoglycosides and tetracy-
clines. Carbapenems are the drugs of choice 
against UTIs caused by E. coli and K. pneu-
moniae. The higher MDR in this region is a 
cause of concern. The findings suggest per-
sistent increasing trend of antibiotic re-
sistance and proportion of ESBLs production 
by the organism. This indicates the need to 
focus on regulatory affairs for constant sur-
veillance, proper antibiotic administration 
and application of stringent infection control 
processes in order to decrease ESBL fre-
quency. Also, further molecular studies are 
recommended to elucidate the basis of this 
multidrug resistance and ESBL production. 
In conclusion, the fraction of ESBL-
producing isolates is increasing with time 
that shows higher resistance to a wide 
variety of commonly used antibiotics as 
compared to the non-ESBL-producers. The 
antibiotics showing greater susceptibility 
towards E. coli and K. pneumoniae isolates 
are imipenem, piperacillin-tazobactam, 
ampicillin-sulbactam and amikacin. The 
antibiotics having the highest resistance, 
particularly against the ESBL producers 
were amoxycillin clavulanic acid, sulpha-
methoxalzole/trimethoprim, cefuroxime, 
cefpirome, ceftriaxone and ciprofloxacin and 
should be removed from the line of treatment 
for common urinary tract infections. It is 
strongly recommended to follow the ‘Good 
Clinical Practices’ and not to prescribe drugs 
without appropriate lab tests. Proper counsel-
ing of patients should be mandatory for 
proper and complete courses of medications 
to avoid the evolution of resistant strains. 
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